These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30922102)

  • 1. Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism.
    Pardiñas AF; Nalmpanti M; Pocklington AJ; Legge SE; Medway C; King A; Jansen J; Helthuis M; Zammit S; MacCabe J; Owen MJ; O'Donovan MC; Walters JTR
    Am J Psychiatry; 2019 Jun; 176(6):477-486. PubMed ID: 30922102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data.
    Pardiñas AF; Kappel DB; Roberts M; Tipple F; Shitomi-Jones LM; King A; Jansen J; Helthuis M; Owen MJ; O'Donovan MC; Walters JTR
    Lancet Psychiatry; 2023 Mar; 10(3):209-219. PubMed ID: 36804072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine/N-desmethylclozapine on working memory in schizophrenia.
    Islam F; Maciukiewicz M; Freeman N; Huang E; Tiwari A; Mulsant BH; Pollock BG; Remington G; Kennedy JL; Müller DJ; Rajji TK
    J Psychopharmacol; 2021 Jan; 35(1):31-39. PubMed ID: 33143542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.
    Okhuijsen-Pfeifer C; van der Horst MZ; Bousman CA; Lin B; van Eijk KR; Ripke S; Ayhan Y; Babaoglu MO; Bak M; Alink W; van Beek H; Beld E; Bouhuis A; Edlinger M; Erdogan IM; Ertuğrul A; Yoca G; Everall IP; Görlitz T; ; Grootens KP; Gutwinski S; Hallikainen T; Jeger-Land E; de Koning M; Lähteenvuo M; Legge SE; Leucht S; Morgenroth C; Müderrisoğlu A; Narang A; Pantelis C; Pardiñas AF; Oviedo-Salcedo T; Schneider-Thoma J; Schreiter S; Repo-Tiihonen E; Tuppurainen H; Veereschild M; Veerman S; de Vos M; Wagner E; Cohen D; Bogers JPAM; Walters JTR; Yağcıoğlu AEA; Tiihonen J; Hasan A; Luykx JJ
    Transl Psychiatry; 2022 Apr; 12(1):145. PubMed ID: 35393395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and genetic influencing factors on clozapine pharmacokinetics in Tunisian schizophrenic patients.
    Ammar H; Chadli Z; Mhalla A; Khouadja S; Hannachi I; Alshaikheid M; Slama A; Ben Fredj N; Ben Fadhel N; Ben Romdhane H; Chaabane A; Boughattas NA; Gaha L; Zarrouk L; Aouam K
    Pharmacogenomics J; 2021 Oct; 21(5):551-558. PubMed ID: 33731885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics.
    Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia AG; Ventimiglia A; Perucca E
    Psychopharmacology (Berl); 2000 Jan; 148(1):83-9. PubMed ID: 10663421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity.
    Lesche D; Mostafa S; Everall I; Pantelis C; Bousman CA
    Pharmacogenomics J; 2020 Apr; 20(2):192-201. PubMed ID: 31616047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
    Ozdemir V; Kalow W; Posner P; Collins EJ; Kennedy JL; Tang BK; Albers LJ; Reist C; Roy R; Walkes W; Afra P
    J Clin Psychopharmacol; 2001 Aug; 21(4):398-407. PubMed ID: 11476124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM.
    Amin N; Byrne E; Johnson J; Chenevix-Trench G; Walter S; Nolte IM; ; Vink JM; Rawal R; Mangino M; Teumer A; Keers JC; Verwoert G; Baumeister S; Biffar R; Petersmann A; Dahmen N; Doering A; Isaacs A; Broer L; Wray NR; Montgomery GW; Levy D; Psaty BM; Gudnason V; Chakravarti A; Sulem P; Gudbjartsson DF; Kiemeney LA; Thorsteinsdottir U; Stefansson K; van Rooij FJ; Aulchenko YS; Hottenga JJ; Rivadeneira FR; Hofman A; Uitterlinden AG; Hammond CJ; Shin SY; Ikram A; Witteman JC; Janssens AC; Snieder H; Tiemeier H; Wolfenbuttel BH; Oostra BA; Heath AC; Wichmann E; Spector TD; Grabe HJ; Boomsma DI; Martin NG; van Duijn CM
    Mol Psychiatry; 2012 Nov; 17(11):1116-29. PubMed ID: 21876539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.
    Ruderfer DM; Charney AW; Readhead B; Kidd BA; Kähler AK; Kenny PJ; Keiser MJ; Moran JL; Hultman CM; Scott SA; Sullivan PF; Purcell SM; Dudley JT; Sklar P
    Lancet Psychiatry; 2016 Apr; 3(4):350-7. PubMed ID: 26915512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption.
    Sulem P; Gudbjartsson DF; Geller F; Prokopenko I; Feenstra B; Aben KK; Franke B; den Heijer M; Kovacs P; Stumvoll M; Mägi R; Yanek LR; Becker LC; Boyd HA; Stacey SN; Walters GB; Jonasdottir A; Thorleifsson G; Holm H; Gudjonsson SA; Rafnar T; Björnsdottir G; Becker DM; Melbye M; Kong A; Tönjes A; Thorgeirsson T; Thorsteinsdottir U; Kiemeney LA; Stefansson K
    Hum Mol Genet; 2011 May; 20(10):2071-7. PubMed ID: 21357676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine: four case reports].
    Papetti F; Morel-Pingault V; Buisse V; Maziere L; Banayan M; Thauby S; Besnard T; Darcourt G; Pringuey D
    Encephale; 2007 Oct; 33(5):811-8. PubMed ID: 18357853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of clozapine-related metabolic disturbances with CYP3A4 expression in patients with schizophrenia.
    Menus Á; Kiss Á; Tóth K; Sirok D; Déri M; Fekete F; Csukly G; Monostory K
    Sci Rep; 2020 Dec; 10(1):21283. PubMed ID: 33277605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics.
    Tóth K; Csukly G; Sirok D; Belic A; Kiss Á; Háfra E; Déri M; Menus Á; Bitter I; Monostory K
    Int J Neuropsychopharmacol; 2017 Jul; 20(7):529-537. PubMed ID: 28340122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia.
    Ferrari M; Bolla E; Bortolaso P; Callegari C; Poloni N; Lecchini S; Vender S; Marino F; Cosentino M
    Psychiatry Res; 2012 Dec; 200(2-3):1014-7. PubMed ID: 22901441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics in schizophrenia: the quest for individualized therapy.
    Basile VS; Masellis M; Potkin SG; Kennedy JL
    Hum Mol Genet; 2002 Oct; 11(20):2517-30. PubMed ID: 12351588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.
    Ozdemir V; Kalow W; Okey AB; Lam MS; Albers LJ; Reist C; Fourie J; Posner P; Collins EJ; Roy R
    J Clin Psychopharmacol; 2001 Dec; 21(6):603-7. PubMed ID: 11763009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.
    Li LJ; Shang DW; Li WB; Guo W; Wang XP; Ren YP; Li AN; Fu PX; Ji SM; Lu W; Wang CY
    Acta Pharmacol Sin; 2012 Nov; 33(11):1409-16. PubMed ID: 22820910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cigarette smoking has a differential effect on the plasma level of clozapine in Taiwanese schizophrenic patients associated with the CYP1A2 gene -163A/C single nucleotide polymorphism.
    Huang HC; Lua AC; Wu LS; Wu BJ; Lee SM; Liu CZ
    Psychiatr Genet; 2016 Aug; 26(4):172-7. PubMed ID: 27203225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy.
    Légaré N; Grégoire CA; De Benedictis L; Dumais A
    Med Hypotheses; 2013 Jun; 80(6):689-91. PubMed ID: 23490199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.